Clinical Trial Update: A Single Arm Study Evaluating the Efficacy, Safety and Tolerability of Ofatumumab in Patients With Relapsing Multiple Sclerosis [Phase 3]

View source ↗

Summary

Phase 3 single-arm trial evaluating the efficacy, safety and tolerability of ofatumumab in Relapsing Multiple Sclerosis has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Relapsing Multiple Sclerosis

Drugs mentioned

• Kesimpta (ofatumumab)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Relapsing Multiple Sclerosis | Phase 3 | Status: COMPLETED | Results posted: 2024-11-01